RxDoctor Payments DataLook up a doctor →

Daniel Sajewski, MD

Anesthesiology · Roslyn, NYNPI 1669485041

Payments from drug & device makers

$76,213in general payments, 2019–2025

Across 434 payments — averaging $175.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cumberland Pharmaceuticals, Inc.$67K
  • Abbott$2K
  • AbbVie$1K
  • Vertos Medical, Inc.$1K
  • Acelrx Pharmaceuticals, Inc.$961
  • Scilex Pharmaceuticals Inc.$707
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$7,0579%
  • Speaking & faculty fees$54,98072%
  • Travel & lodging$2,8674%
  • Food & beverage$10,84814%
  • Education$3020%
  • Entertainment$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,213 in reported general payments places this provider in the 95th percentile of 4,157 anesthesiology providers in New York.

See all anesthesiology providers in New York

Medicare billing

Part B allowed, 2024
$183,374
Medicare patients
499
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl59$59,006
NucyntaTapentadol Hcl14$21,303
BelbucaBuprenorphine Hcl11$10,800
Fentanyl88$7,445
Oxycodone Hcl258$6,517
Pregabalin26$5,244
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen94$4,527
Lubiprostone21$2,403
Morphine Sulfate ErMorphine Sulfate78$2,265
Lidocaine13$1,863
Tizanidine Hcl114$1,384
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$1,084
Methadone Hcl36$907
Gabapentin71$900
Cyclobenzaprine Hcl40$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca$198$32,10325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,157 anesthesiology providers in New York.

Other anesthesiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →